Leading Cancer Center Adopts Abridge AI for Oncology Documentation Abridge, a leader in AI-driven clinical documentation solutions, has announced an extensive rollout of its AI platform at Memorial Sloan Kettering…
Estrella Immunopharma Receives Buy Rating from CB Capital Partners with a $14.00 Price Target Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development…
Alnylam Announces Retirement of Co-Founder and Esteemed Board Member Dr. Phillip A. Sharp Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the pioneering leader in RNA interference (RNAi) therapeutics, today announced the retirement…
Bicycle Therapeutics Announces Inducement Grants Bicycle Therapeutics plc (NASDAQ: BCYC), a pioneering biotechnology company focused on developing a new class of therapeutics known as Bicycle® molecules, announced that on March…
LEO Pharma Survey: Chronic Hand Eczema Misunderstood and Undermanaged LEO Pharma Survey Highlights Widespread Misunderstanding and Inadequate Management of Chronic Hand Eczema Among Dermatology Providers A recent survey commissioned by…
Orbis Medicines Appoints Industry Veteran Mikael Dolsten as Board Chair Orbis Medicines, a pioneering leader in oral macrocycle drug discovery, has announced the appointment of Mikael Dolsten, M.D., Ph.D., as…
FDA Accepts sBLA for Genentech’s Gazyva in Lupus Nephritis Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced that the U.S. Food and Drug Administration…
Bionova Launches New Process Development and Pilot Plant in Fremont Bionova Scientific, an Asahi Kasei company and boutique commercial-scale biologics contract development and manufacturing organization (CDMO), has officially announced the…
GeneDx Expands Exome and Genome Testing Access, Adding Cerebral Palsy as a New Indication GeneDx (Nasdaq: WGS), a leading innovator in genomic insights, has announced an expansion of its genetic…
Cadrenal Therapeutics Partners with Abbott for Pivotal Tecarfarin Study in HeartMate 3™ LVAD Patients Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company specializing in the development of cardiovascular therapeutics,…
Epredia Secures FDA 510(k) Clearance for E1000 Dx™ Digital Pathology Solution Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), has announced…
Parse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products Parse Biosciences, a leading innovator in scalable and accessible single-cell sequencing technology, has reaffirmed its commitment to advancing its Evercode™ single-cell…